Outcomes with Endovascular Treatment of Patients with M2 Segment MCA Occlusion in the Late Time Window.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
04 2023
Historique:
received: 29 10 2022
accepted: 23 02 2023
pmc-release: 01 04 2024
medline: 12 4 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: ppublish

Résumé

Randomized trials in the late window have demonstrated the efficacy and safety of endovascular thrombectomy in large-vessel occlusions. Patients with M2-segment MCA occlusions were excluded from these trials. We compared outcomes with endovascular thrombectomy in patients with M2-versus-M1 occlusions presenting 6-24 hours after symptom onset. Analyses were on pooled data from studies enrolling patients with stroke treated with endovascular thrombectomy 6-24 hours after symptom onset. We compared 90-day functional independence (mRS ≤ 2), mortality, symptomatic intracranial hemorrhage, and successful reperfusion (expanded TICI = 2b-3) between patients with M2 and M1 occlusions. The benefit of successful reperfusion was then assessed among patients with M2 occlusion. Of 461 patients, 367 (79.6%) had M1 occlusions and 94 (20.4%) had M2 occlusions. Patients with M2 occlusions were older and had lower median baseline NIHSS scores. Patients with M2 occlusion were more likely to achieve 90-day functional independence than those with M1 occlusion (adjusted OR = 2.13; 95% CI, 1.25-3.65). There were no significant differences in the proportion of successful reperfusion (82.9% versus 81.1%) or mortality (11.2% versus 17.2%). Symptomatic intracranial hemorrhage risk was lower in patients with M2-versus-M1 occlusions (4.3% versus 12.2%, In the late time window, patients with M2 occlusions treated with endovascular thrombectomy achieved better clinical outcomes, similar reperfusion, and lower symptomatic intracranial hemorrhage rates compared with patients with M1 occlusion. These results support the safety and benefit of endovascular thrombectomy in patients with M2 occlusions in the late window.

Sections du résumé

BACKGROUND AND PURPOSE
Randomized trials in the late window have demonstrated the efficacy and safety of endovascular thrombectomy in large-vessel occlusions. Patients with M2-segment MCA occlusions were excluded from these trials. We compared outcomes with endovascular thrombectomy in patients with M2-versus-M1 occlusions presenting 6-24 hours after symptom onset.
MATERIALS AND METHODS
Analyses were on pooled data from studies enrolling patients with stroke treated with endovascular thrombectomy 6-24 hours after symptom onset. We compared 90-day functional independence (mRS ≤ 2), mortality, symptomatic intracranial hemorrhage, and successful reperfusion (expanded TICI = 2b-3) between patients with M2 and M1 occlusions. The benefit of successful reperfusion was then assessed among patients with M2 occlusion.
RESULTS
Of 461 patients, 367 (79.6%) had M1 occlusions and 94 (20.4%) had M2 occlusions. Patients with M2 occlusions were older and had lower median baseline NIHSS scores. Patients with M2 occlusion were more likely to achieve 90-day functional independence than those with M1 occlusion (adjusted OR = 2.13; 95% CI, 1.25-3.65). There were no significant differences in the proportion of successful reperfusion (82.9% versus 81.1%) or mortality (11.2% versus 17.2%). Symptomatic intracranial hemorrhage risk was lower in patients with M2-versus-M1 occlusions (4.3% versus 12.2%,
CONCLUSIONS
In the late time window, patients with M2 occlusions treated with endovascular thrombectomy achieved better clinical outcomes, similar reperfusion, and lower symptomatic intracranial hemorrhage rates compared with patients with M1 occlusion. These results support the safety and benefit of endovascular thrombectomy in patients with M2 occlusions in the late window.

Identifiants

pubmed: 36958801
pii: ajnr.A7833
doi: 10.3174/ajnr.A7833
pmc: PMC10084904
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-452

Informations de copyright

© 2023 by American Journal of Neuroradiology.

Références

J Stroke. 2019 Sep;21(3):332-339
pubmed: 31590477
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
J Neurointerv Surg. 2022 May;14(5):
pubmed: 34045317
J Stroke Cerebrovasc Dis. 2020 Sep;29(9):105018
pubmed: 32807433
Stroke. 2021 May;52(5):1534-1544
pubmed: 33739136
J Neurointerv Surg. 2018 Jul;10(7):620-624
pubmed: 29127196
J Neurointerv Surg. 2016 Dec;8(12):1273-1277
pubmed: 26863104
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
AJNR Am J Neuroradiol. 2018 Jan;39(1):102-106
pubmed: 29191873
Stroke. 2021 Aug;52(9):2736-2742
pubmed: 34233462
Neurology. 2020 Jul 14;95(2):e131-e139
pubmed: 32527972
J Neurointerv Surg. 2018 Nov;10(11):1043-1046
pubmed: 29459367
AJNR Am J Neuroradiol. 2020 Feb;41(2):280-285
pubmed: 32001443
Stroke. 2020 Jul;51(7):2051-2057
pubmed: 32568647
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Lancet. 2020 Mar 14;395(10227):878-887
pubmed: 32087818
World Neurosurg. 2021 Jul;151:e871-e879
pubmed: 33974981
J Neurointerv Surg. 2022 May;14(5):
pubmed: 34035151
AJNR Am J Neuroradiol. 2020 Jan;41(1):129-133
pubmed: 31806593
J Neurointerv Surg. 2022 Apr;14(4):350-355
pubmed: 33947769
J Neurointerv Surg. 2019 Nov;11(11):1065-1069
pubmed: 30975736
JAMA Neurol. 2016 Nov 01;73(11):1291-1296
pubmed: 27617425
Clin Neuroradiol. 2020 Sep;30(3):481-487
pubmed: 31338541
J Neurointerv Surg. 2021 Sep;13(9):779-783
pubmed: 33219148
J Neurointerv Surg. 2020 Mar;12(3):279-282
pubmed: 31243066
J Neurol Neurosurg Psychiatry. 2022 May;93(5):468-474
pubmed: 35086938
Lancet. 2022 Jan 15;399(10321):249-258
pubmed: 34774198
Stroke. 2020 May;51(5):1539-1545
pubmed: 32268851
World Neurosurg. 2019 Oct;130:e1098-e1104
pubmed: 31323418
J Neurointerv Surg. 2021 Nov;13(11):979-984
pubmed: 33323503
J Neurointerv Surg. 2020 Sep;12(9):842-847
pubmed: 31772044
Stroke. 2021 Nov;52(11):3490-3496
pubmed: 34311566
J Neurointerv Surg. 2018 Apr;10(4):330-334
pubmed: 28705890
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396

Auteurs

F Bala (F)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.
Diagnostic and Interventional Neuroradiology Department (F.B.), University Hospital of Tours, Tours, France.

B J Kim (BJ)

Department of Neurology and Cerebrovascular Center (B.J.K.), Seoul National University Bundang Hospital, Seoul, Republic of Korea.

M Najm (M)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.

J Thornton (J)

Neuroradiology Department (J.T., D.H., S.P.).
Royal College of Surgeons in Ireland (J.T., A.H.), Dublin, Ireland.

E Fainardi (E)

Neuroradiology Unit (E.F.), Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.

P Michel (P)

Stroke Center (P.M., S.N.), Neurology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

K Alpay (K)

Department of Radiology (K.A., R.R.), Turku University Hospital, Turku, Finland.

D Herlihy (D)

Neuroradiology Department (J.T., D.H., S.P.).

M Goyal (M)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.

I Casetta (I)

Clinica Neurologica (I.C.), University of Ferrara, Ferrara, Italy.

S Nannoni (S)

Stroke Center (P.M., S.N.), Neurology Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

P Ylikotila (P)

Neurocenter (P.Y.), Turku University Hospital, University of Turku, Turku, Finland.

S Power (S)

Neuroradiology Department (J.T., D.H., S.P.).

V Saia (V)

Stroke Unit (V.S.), Santa Corona Hospital, Pietra Ligure, Italy.

A Hegarty (A)

Royal College of Surgeons in Ireland (J.T., A.H.), Dublin, Ireland.

G Pracucci (G)

Stroke Unit (G.P.), Careggi University Hospital, Florence, Italy.

R Rautio (R)

Department of Radiology (K.A., R.R.), Turku University Hospital, Turku, Finland.

A Ademola (A)

Department of Community Health Sciences (A.A., M.D.H., B.K.M., M.A.A.), University of Calgary, Calgary, Alberta, Canada.

A Demchuk (A)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.

S Mangiafico (S)

Interventional Neuroradiology Unit (S. Mangiafico), Institute for Hospitalization and Healthcare Neuromed, Pozzilli, Italy.

K Boyle (K)

Department of Geriatric and Stroke Medicine (K.B.), Beaumont Hospital, Dublin, Ireland.

M D Hill (MD)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences (A.A., M.D.H., B.K.M., M.A.A.), University of Calgary, Calgary, Alberta, Canada.

D Toni (D)

Emergency Department (D.T.), Stroke Unit, Sapienza University Hospital, Rome, Italy.

S Murphy (S)

Department of Geriatric and Stroke Medicine (S. Murphy), The Mater Misericordiae University Hospital, Dublin, Ireland.
School of Medicine (S. Murphy), Royal College of Surgeons in Ireland, Dublin, Ireland.
School of Medicine (S. Murphy), University College Dublin, Dublin, Ireland.

B K Menon (BK)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences (A.A., M.D.H., B.K.M., M.A.A.), University of Calgary, Calgary, Alberta, Canada.

M A Almekhlafi (MA)

From the Calgary Stroke Program (F.B., M.N., M.G., A.D., M.D.H., B.K.M., M.A.A.), Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada mohammed.almekhlafi1@ucalgary.ca.
Department of Community Health Sciences (A.A., M.D.H., B.K.M., M.A.A.), University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH